Why Achieve Life Sciences, Inc.’s (ACHV) Stock Is Up 7.41%
As of Thursday, September 17, Achieve Life Sciences, Inc.’s ACHV share price has surged by 7.41%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Commentary & Analysis
Why Achieve Life Sciences, Inc.’s (ACHV) Stock Is Up 6.36%
As of Friday, August 21, Achieve Life Sciences, Inc.’s ACHV share price has surged by 6.36%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Achieve Life Sciences, Inc.’s (ACHV) Stock Is Up 5.52%
As of Wednesday, August 19, Achieve Life Sciences, Inc.’s ACHV share price has surged by 5.52%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Achieve Life Sciences, Inc.’s (ACHV) Stock Is Up 5.70%
As of Thursday, August 13, Achieve Life Sciences, Inc.’s ACHV share price has surged by 5.70%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Achieve Life Sciences, Inc.’s (ACHV) Stock Is Up 5.62%
As of Friday, July 17, Achieve Life Sciences, Inc.’s ACHV share price has surged by 5.62%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ACHV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $835.6 | $271.9 | 43% |
|
| Shares Out (Mil) | 93.5 | 54.2 | 60% |
|
| Institutional Ownership | 96.3% | 92.9% | 69% |
|
| Float (Mil) | 74.7 | 42.1 | 55% |
|
| Beta | 2.25 | 0.95 | 94% |
|
| Avg Daily Volume (000s) | 1,841 | 612 | 79% |
|
| Price Change (52-week) |
187.9% | 56.0% | 97% |
|
| Growth | ACHV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.1% | na |
|
| Net Income (5yr) | (30.0%) | (10.1%) | 14% |
|
| EPS (5yr) | 25.4% | 15.7% | 76 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (51.5%) | (15.6%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 10 | 11 | |
| Current EPS | ($0.193) | ($1.371) | ($0.636) | |
| Month Ago EPS | ($0.193) | ($1.371) | ($0.636) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.163) | ($0.693) | ($0.464) | |
| Year/Year Chg | (75.9%) | 9.3% | (113.1%) | |
| Financials | ACHV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($114) | ($43) | 10% |
|
| EPS (TTM) | ($1.809) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($47) | ($32) | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($4) | $2 | 35% |
|
| Long-Term Debt (Q1) (Mil) | $8 | $4 | 27% |
|
| Enterprise Value (Q1) (Mil) | $649 | $177 | 36% |
|
| Valuation | ACHV | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.67 | na |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ACHV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.0% | na |
|
| Net Margin | na | (71.5%) | na |
|
| ROA | (91.5%) | (47.4%) | 6% |
|
| ROE | (845.0%) | (54.6%) | 0% |
|
| Liabilities to Assets | 107.7% | 29.3% | 95% |
|
| F-Score | 2 | 3 | 7% |
|
Achieve Life Sciences, Inc. did not pass any screens on 9/22/2026.
